Hemophagocytic lymphohistiocytosis complicating invasive pneumococcal disease: a pediatric case report by Tsuge, Mitsuru et al.
CASE REPORT Open Access
Hemophagocytic lymphohistiocytosis
complicating invasive pneumococcal
disease: a pediatric case report
Mitsuru Tsuge1* , Machiko Miyamoto2, Reiji Miyawaki3, Yoichi Kondo2 and Hirokazu Tsukahara1
Abstract
Background: Hemophagocytic lymphohistiocytosis (HLH) is an infrequent but life-threatening disease due to
excessive immune activation. Secondary HLH can be triggered by infections, autoimmune diseases, and malignant
diseases. Streptococcus pneumoniae is a pathogenic bacterium responsible for invasive pneumococcal disease (IPD)
such as meningitis and bacteremia. Although the pneumococcal conjugate vaccine (PCV) has led to reductions in
IPD incidence, cases of IPD caused by serotypes not included in PCV are increasing. There are few reports of
secondary HLH caused by IPD in previously healthy children. We herein report a rare case of a previously healthy
boy with secondary HLH complicating IPD of serotype 23A, which is not included in the pneumococcal 13-valent
conjugate vaccine (PCV-13).
Case presentation: An 11-month-old boy who had received three doses of PCV-13 was hospitalized with
prolonged fever, bilateral otitis media, neutropenia and elevated C-reactive protein (CRP) levels. Blood culture on
admission revealed S. pneumoniae, leading to a diagnosis of IPD. HLH was diagnosed based on a prolonged fever,
neutropenia, anemia, hepatosplenomegaly, hemophagocytosis in the bone marrow, and elevated serum levels of
triglycerides, ferritin, and soluble interleukin-2 receptor. He received broad-spectrum antibiotics and intravenous
immunoglobulins for IPD and high-dose steroid pulse therapy and cyclosporine A for HLH; thereafter, his fever
resolved, and laboratory findings improved. The serotype of the isolated S. pneumoniae was 23A, which is not
included in PCV-13.
Conclusions: It is important to consider secondary HLH as a complication of IPD cases with febrile cytopenia or
hepatosplenomegaly, and appropriate treatment for HLH should be started without delay.
Keywords: Child, Hemophagocytic lymphohistiocytosis, Invasive pneumococcal disease, Pneumococcal conjugate
vaccine, Serotype replacement
Background
Hemophagocytic lymphohistiocytosis (HLH) is an infre-
quent but potentially life-threatening hematological dis-
order associated with an excessive systemic inflammatory
response [1, 2]. It is caused by uncontrolled activation and
proliferation of macrophages, lymphocytes, and dendritic
cells, resulting in hemophagocytosis and cytokine storm.
HLH can occur as a primary disorder, caused by a genetic
mutation, or as secondary sporadic cases triggered by
infection, autoimmune diseases, immunodeficiency, or
malignant diseases. Viruses are the most common cause
of infection-associated HLH, with Epstein Barr virus
(EBV) being the most common trigger. Particularly in
children, virus-associated HLH accounts for 94% of
infection-associated HLH, and approximately half of the
virus-associated HLH cases are caused by EBV [3]. Bacter-
ial, fungal, parasitic, and tropical infections can also trigger
HLH; however, there are very few reports of bacterial-
associated HLH in children.
Streptococcus pneumonia is an important pathogen
causing invasive infections such as pneumonia, meningi-
tis, and bacteremia, leading to high morbidity and mor-
tality. The pneumococcal conjugate vaccine (PCV) has
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led to dramatic reductions in cases of invasive pneumo-
coccal disease (IPD) worldwide, including Japan; how-
ever, IPD cases caused by serotypes not included in the
13-valent pneumococcal conjugate vaccine (PCV-13) are
becoming increasingly frequent due to serotype replace-
ment [4, 5].
Secondary HLH caused by S. pneumoniae has been
previously described as a complication of IPD in immu-
nodeficient children; however, there are few reports in
previously healthy children. We describe a rare case of a
previously healthy boy with secondary HLH caused by
IPD due to S. pneumoniae 23A, which is not included in
the PCV-13.
Case presentation
An 11-month-old, previously healthy boy with a 1-day
history of fever was presented to his family physician.
Blood tests revealed leukocytosis (10,000 /μL) and an el-
evated C-reactive protein (CRP) level (5.0 mg/dL). His
family physician suspected that he was suffering from
mild pneumonia, and he was administered a single intra-
venous dose of ceftriaxone sodium and discharged on
daily suppository antibiotics (ceftizoxime sodium) and
then sent home. However, his fever persisted, so he was
taken to consult the family physician every day. His fam-
ily physician advised that he continue using antibiotics;
however, progressive neutropenia and an increased CRP
level were shown. He was therefore referred to our
hospital.
His parents were not consanguineous, and there were
no cases of immunodeficiency or HLH in the patient’s
family. He had no remarkable medical history and his
physical growth and development had been normal. He
had been fully immunized with three doses of PCV-13.
A physical examination on admission revealed that his
temperature was 41.1 °C, blood pressure was 88/58
mmHg, heart rate was 202 beats/min, respiratory rate was
60/min, and SpO2 was 100%. He showed a normal growth
and development. He had conjunctival pallor, dried lips,
reddened pharyngeal mucosa, bilateral inflamed eardrums,
hepatosplenomegaly, and petechiae on his extremities.
The blood tests revealed leukopenia (1570 /μL), neutro-
penia (63 /μL), increased CRP (37.8 mg/dL), increased
procalcitonin (PCT) (97mg/dL), increased aspartate ami-
notransferase (AST) (287 IU/L), increased lactate dehydro-
genase (LDH) (3474 IU/L), increased fibrin/fibrinogen
degradation products (FDP) (1257 μg/mL), hyperferritine-
mia (26,500 ng/mL), hypertriglyceridemia (389mg/dL),
and increased soluble IL-2 receptor (sIL-2R) (4400 U/mL)
(Table 1). A blood test on the second day of admission
showed anemia (7.8 g/dL). Serum electrolytes, blood urea
nitrogen, blood sugar, and serum creatinine levels were
within normal range. The results of the urinalysis was nor-
mal. Leukocytosis was absent in the cerebrospinal fluid
(CSF), and the concentrations of protein and glucose in
the CSF were within the reference range (31mg/dL and
53mg/dL, respectively). There was no evidence EBV on
serology or DNA in whole blood. The immunoglobulin M
titers for cytomegalovirus, human herpesvirus-6, and mea-
sles were also negative. The results of immunochromato-
graphic antigen tests for influenza virus in nasal discharge,
adenovirus in throat swab, rotavirus in stool, human
metapneumovirus in nasal discharge, and group A
Streptococcus in throat swab were negative. The β-D-
glucan level was also negative.
Computed tomography revealed hepatosplenomegaly
without pleural effusion, ascites, or abscess. Cerebral
magnetic resonance imaging revealed fluid retention in
the bilateral mastoid processes. Echocardiography re-
vealed no pericardial effusion, valve vegetations, or cor-
onary artery dilation. To differentiate other causes of
neutropenia and anemia, bone marrow puncture was
performed, revealing that the number of nucleated cells
was decreased (2.0 × 104/μL), and the ratio of myeloid to
erythroid precursor cells was increased to 9.29. Phago-
cytosis of erythroblasts by macrophages was observed.
After submitting blood cultures, meropenem hydrate
was started on admission. We diagnosed him with severe
IPD with a rapid progressive deterioration in his general
condition and a severe systemic inflammatory response;
therefore, intravenous immunoglobulin was also admin-
istered as an add-on antimicrobial therapy. In addition,
he was diagnosed with HLH based on prolonged fever;
neutropenia; anemia; hepatosplenomegaly; hemophago-
cytosis in the bone marrow; and elevated serum levels of
triglycerides, ferritin, and sIL-2R.
On the second day of hospitalization, S. pneumoniae
was isolated from blood cultures drawn on admission.
Cultures from urine and CSF samples were negative. We
explained to the patient’s parents that the prompt treat-
ment for HLH with immunomodulatory therapy using
steroid and immunosuppressants was needed, and that
these treatments might have an adverse effect on the se-
verity of the IPD; thereafter, we obtained a consent for
treatment from the patient’s parents. On the same day,
high-dose methylprednisolone (30 mg/kg/day, 3 days)
was started. Prednisolone (1.5 mg/kg/day) and cyclo-
sporin A (6 mg/kg/day) were started after the methyl-
prednisolone pulse; thereafter, white blood cell count,
neutrophil count, and platelet counts gradually increased
while the levels of AST, LDH, FDP, ferritin, and CRP
returned to their normal ranges. The minimum inhibi-
tory concentration (MIC) of penicillin G for the detected
S. pneumoniae was 0.5 μg/mL; therefore, it was identified
as penicillin-intermediate S. pneumoniae (PISP). On the
fourth day of hospitalization, his fever resolved. He was
then switched to cefotaxime sodium (150 mg/kg/day) as
de-escalation, although the MIC of cefotaxime was not
Tsuge et al. BMC Pediatrics           (2020) 20:15 Page 2 of 6
Ta
b
le
1
Se
ria
lc
ha
ng
es
in
in
fla
m
m
at
or
y
pa
ra
m
et
er
s
du
rin
g
in
va
si
ve
pn
eu
m
oc
oc
ca
ld
is
ea
se
w
ith
he
m
op
ha
go
cy
tic
ly
m
ph
oh
is
tio
cy
to
si
s
D
ay
s
of
H
os
pi
ta
liz
at
io
n
(re
fe
re
nc
e
ra
ng
e)
W
BC
(/
μl
)
(3
50
0–
90
00
)
N
EC
(/
μl
)
(1
24
0–
46
10
)
H
gb
(g
/d
l)
(1
3.
6–
18
.3
)
PL
T
(×
10
4 /
μl
)
(1
4.
0–
37
.9
)
C
RP
(m
g/
dl
)
(0
–0
.5
)
PC
T
(n
g/
m
l)
(<
0.
5)
A
ST
(IU
/l)
(1
0–
40
)
LD
H
(IU
/l)
(1
20
–
24
5)
FD
P
(μ
g/
m
l)
(<
5)
Fe
rr
iti
n
(p
g/
m
l)
(3
8–
15
0)
U
rin
ar
y
β2
M
G
(n
g/
m
l)
(0
–
28
9)
sI
L-
2R
(U
/m
l)
(1
45
–
51
9)
IL
-6
(p
g/
m
l)
(0
–1
49
)
IL
-1
0
(p
g/
m
l)
(<
8)
IL
-1
8
(p
g/
m
l)
(<
10
0)
IF
N
-γ
(p
g/
m
l)
(<
2)
sC
D
16
3
(p
g/
m
l)
(<
10
0)
-4
10
,0
00
43
30
11
.1
20
.1
5.
0
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
−
3
89
00
32
22
10
.7
22
.9
7.
1
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
−
2
59
00
10
80
11
.1
20
.1
7.
9
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
−
1
42
00
0
9.
5
13
.4
6.
5
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
N
D
0
15
70
63
9.
1
17
.5
37
.8
97
28
7
34
74
12
57
26
,5
00
59
,2
47
44
00
53
66
82
64
6
34
.5
61
8
2
70
0
7
7.
8
13
.8
34
.3
77
18
7
25
37
11
4
16
,9
50
59
,4
88
69
46
39
9
10
9
19
28
12
.3
53
1
4
56
90
29
02
11
.6
20
.3
17
.5
13
89
97
9
17
41
70
19
3,
96
0
36
01
10
3
17
83
8
10
46
0
7
36
,1
30
20
,5
94
9.
1
18
.4
3.
3
1.
2
39
61
7
14
38
5
29
5
16
23
11
5.
9
45
7
7.
1
25
3
10
23
,3
30
13
,2
98
9.
5
48
.0
1.
4
0.
8
52
49
4
6.
1
21
3
24
5
99
4
7.
7
4.
2
31
6
7.
1
18
9
14
13
,2
40
39
72
8.
3
61
.0
0.
2
0.
7
30
31
2
2.
8
10
7
12
2
37
2
6.
8
3.
8
20
6
7.
1
11
5
17
83
00
19
09
7.
9
54
.7
0.
1
0.
8
27
24
7
2.
3
62
95
34
9
4.
0
2.
8
87
7.
1
62
W
BC
W
hi
te
bl
oo
d
ce
ll
co
un
t,
N
EC
N
eu
tr
op
hi
lc
ou
nt
,H
gb
H
em
og
lo
bi
n,
PL
T
Pl
at
el
et
co
un
t,
CR
P
C
-r
ea
ct
iv
e
pr
ot
ei
n,
PC
T
Pr
oc
al
ci
to
ni
n,
A
ST
A
sp
ar
ta
te
am
in
ot
ra
ns
fe
ra
se
,L
D
H
La
ct
at
e
de
hy
dr
og
en
as
e,
FD
P
Fi
br
in
/f
ib
rin
og
en
de
gr
ad
at
io
n
pr
od
uc
ts
,β
2M
G
Be
ta
-2
m
ic
ro
gl
ob
ul
in
,s
IL
-2
R
So
lu
bl
e
in
te
rle
uk
in
-2
re
ce
pt
or
,I
L
In
te
rle
uk
in
,N
D
N
o
da
ta
Tsuge et al. BMC Pediatrics           (2020) 20:15 Page 3 of 6
relatively good (0.5 μg/mL). Blood culture tests on the
4th, 8th, and 11th days of hospitalization were negative.
Cefotaxime sodium was discontinued on the 14th day of
hospitalization, whereas prednisolone and cyclosporin A
were discontinued on the 55th day of treatment. He was
discharged without any complications on the 22nd day
of hospitalization. There was no recurrence of HLH and
no developmental delay up to when he was 3 years old.
The pneumococcal capsular serotype of S. pneumoniae
isolated from the patient’s blood was identified as 23A,
which was not included in PCV-13. Considering the possi-
bility of primary immunodeficiency, immunological func-
tion tests for the number and function of T cells, B cells,
serum complement titers, serum immunoglobulin titers,
granulocyte phagocytic function, and natural killer cell ac-
tivity were performed and found to be within the normal
range (19.4% assay at effector-to-target ratio of 20:1;
standard value 14.1–48.7%). We did not test the immuno-
globulin G (IgG) titer for S. pneumoniae in this patient;
however, the IgG titer for pertussis was positive, confirm-
ing the reaction of the vaccine that he had previously re-
ceived. In addition to inflammatory parameters such as
CRP, PCT, ferritin, and urinary β2-microglobulin (β2-
MG), we measured serum cytokines such as sIL-2R, inter-
leukin (IL)-2, IL-4, IL-6, IL-10, IL-18, interferon-γ (IFN-
γ), tumor necrosis factor-α (TNF-α), and soluble CD163
(sCD163) serially using the enzyme-linked immunosorb-
ent assay. The levels of CRP, PCT, ferritin, sIL-2R, IL-6,
IL-10, IL-18, IFN-γ, and sCD163 in the serum were highly
peaked at admission and then gradually decreased. How-
ever, the levels of urinary β2-MG remained elevated on
3rd day of hospitalization even after high-dose steroid
pulse therapy and then decreased rapidly after the induc-
tion of cyclosporin A on the 5th day of hospitalization.
The levels of IL-2, IL-4, and TNF-α were below the detec-
tion limit.
Discussion and conclusions
The incidence of pediatric HLH due to bacterial infections
in Japan was reported to be about 6% of the infection-
associated HLH cases [6]. Several studies have reported
bacterial infection-associated HLH [7], including Myco-
plasma pneumoniae [8, 9], Listeria monocytogenes [10],
Leptospira [11], Brucella [12], group B streptococcus [13],
and Coxiella burnetii [14]. Secondary HLH caused by S.
pneumococcus has been previously described in adults
after splenectomy or with primary immunodeficiency [15,
16]. However, there are very few cases of secondary HLH
complicated with IPD in previously healthy children.
In this case, S. pneumoniae was identified in two sets
of blood cultures; therefore, we considered that IPD
could have triggered HLH. Considering that our patient
also had bilateral otitis media, we hypothesized that it
was the source of the blood infection by S. pneumoniae.
Unfortunately, tympanostomy and culture were not per-
formed. The Clinical and Laboratory Standards Institute
criteria for MICs of S. pneumoniae in bacteremia were
used to classify isolates as penicillin-susceptible (≤
0.06 μg/ml), penicillin-intermediate (0.12–1 μg/ml), or
penicillin-resistant (≥ 2 μg/ml). Based on these criteria,
the S. pneumoniae detected in this case was identified as
PISP. Although the MIC of cefotaxime was not very
good (0.5 μg/ml), we were able to perform de-escalation
successfully using cefotaxime sodium at high-dose level.
We also considered the possibilities of other viral or bac-
terial infections. Blood tests and immunochromatographic
antigen tests revealed that the possibility of being infected
with EBV, cytomegalovirus, human herpesvirus-6, measles,
influenza virus, adenovirus, rotavirus, human metapneu-
movirus, and group A streptococcus was less likely; how-
ever, we did not test an exhaustive list of all the possible
pathogens which can cause secondary HLH. There was
also the possibility of primary HLH in this case; one limita-
tion of this case report is that we did not perform perforin
staining, a granule release assay, or a genetic analysis to de-
termine the causes of primary HLH. We are planning these
further analyses for the differentiation of familial hemopha-
gocytic lymphohistiocytosis.
The initial first-line therapy for HLH involves treating
the triggering cause as this can be effective enough to
withdraw the immune activation and control the inflam-
matory cytokine storm in most patients. However, in
acutely ill patients or those whose condition is deteriorat-
ing, immunomodulatory therapy such as a combination of
high-dose steroid, cyclosporine A, and etoposide-based
chemotherapy may be needed, according to the Histiocyte
Society’s diagnostic and therapeutic guidelines for HLH
(HLH-2004) [17]. Our patient also appeared unwell with a
severe systemic inflammatory response; thus, we consid-
ered immunomodulatory therapy to be vital as an early
intervention in the course of the disease.
Viruses are the most common cause of infection-
associated HLH, and the mechanisms by which viruses
contribute to HLH pathogenesis remain to be clarified.
However, it is thought that viruses can increase the host’s
susceptibility to HLH by modulating the host immune
system via recognition by the innate or adaptive immune
system, interfering with cytokine balances, and inhibiting
apoptosis [18]. Serum inflammatory cytokines are known
to be increased in the serum of viral HLH cases, particu-
larly, IFN-γ, TNF-α, IL-6, IL-10, and IL-18 [19]. No report
has described the changes in serum cytokine levels in
cases of bacteria-associated HLH; therefore, we measured
the serial changes in serum cytokines that have been re-
ported previously in cases of virus-associated HLH. In the
present case as well, the levels of IL-6, IL-10, IL-18, and
IFN-γ in the serum were elevated in the acute phase, simi-
lar to the cytokine pattern reported in virus-associated
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HLH [20–22]. The kinetics of the cytokines in our patient
were consistent with those in previous studies that ana-
lyzed patients with pediatric HLH, suggesting that the
cytokine pattern in serum of HLH cases might be similar
even though the susceptibility to HLH varies depending
on the pathogen.
In our case, he suffered from IPD even though he had
already received three doses of PCV-13; the detected S.
pneumoniae serotype was 23A, which is not included in
PCV-13. S. pneumoniae is a causative agent in IPD such
as meningitis and bacteremia, and the incidence rate of
IPD caused by the serotypes included in PCV-13 de-
creased after the introduction of PCV worldwide. In the
United States, IPD was reduced by 75% in 2000 when
PCV-7 (including serotypes 4, 6B, 9 V, 14, 18C, 19P, and
23F) was introduced, and it decreased by 90% after the
introduction of PCV-13 (including the new serotypes 3,
5, 6A, 7F, and 19A) in 2010 [23, 24]. In Japan, PCV-7
was introduced in 2010, and PCV-7 was switched to
PCV-13 as a routine immunization program in 2013. As
a result, the incidence rate of IPD has markedly reduced
[25]. However, serotype replacement has been observed
several years after the introduction of PCV in Japan as
well as worldwide [26, 27]. A recent study reported that
IPD cases caused by serotype 23A account for approxi-
mately 7% of IPD cases in Japan [28].
In conclusion, we described a previously healthy boy
with secondary HLH caused by IPD with a serotype that
is not included in PCV-13. This case suggests that it is
important to consider the complication of secondary
HLH when children with IPD present with unusual clin-
ical findings, such as a prolonged fever, cytopenia, and
hepatosplenomegaly, even if they already received the
PCV in the past or have no past medical history. Prompt
diagnosis and appropriate treatment for HLH should be
provided without delay.
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